Forex
Royal Bank of Canada Raises Pharvaris Price Target Amid Bullish Sentiment
Royal Bank of Canada raised its price target for Pharvaris (NASDAQ:PHVS) from $51.00 to $52.00, a move that suggests a potential upside of 50.48% from the stock's current price.
The brokerage currently has an 'outperform' rating on the stock. This is not the first positive note Pharvaris has received recently; Citizens Jmp raised its target price on shares of Pharvaris from $74.00 to $75.00 and gave the company a 'market outperform' rating.
The biopharmaceutical company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of hereditary angioedema (HAE).